APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cancer Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Cancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025190 pages

Choose your research edition.

Industry ResearchCancer Drugs Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Drugs Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Cancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Drugs Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Drugs Market Analysis and Forecast 2026-2032218 pages · $4,950 USD

Market perspective

The global Cancer Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Cancer Drugs include Takeda, Eisai, Teva, Sanofi, Johnson & Johnson, Novartis, Roche, Eli Lilly and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Cancer Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cancer Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cancer Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cancer Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Cancer Drugs Segment by Company

Takeda

Eisai

Teva

Sanofi

Johnson & Johnson

Novartis

Roche

Eli Lilly

Pfizer

Bayer

Amgen

AbbVie

AstraZeneca

Otsuka

Merck KGaA

Merck & Co.

Ipsen

Gilead Sciences

Celgene

Bristol-Myers Squibb

Biogen Idec

Astellas

Cancer Drugs Segment by Type

Targeted Therapy

Hormonal Therapy (Biologic Therapy)

Chemotherapy

Immunotherapy

Others

Cancer Drugs Segment by Application

Blood Cancer

Gastrointestinal Cancer

Breast Cancer

Prostate Cancer

Respiratory/Lung Cancer

Other Cancers

Cancer Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cancer Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Cancer Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Cancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Cancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Cancer Drugs Industry Trends Table 2. Cancer Drugs Industry Drivers Table 3. Cancer Drugs Industry Opportunities and Challenges Table 4. Cancer Drugs Industry Restraints Table 5. Global Cancer Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Cancer Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Cancer Drugs Sales by Manufacturers (k tons) & (2021-2026) Table 8. Global Cancer Drugs Sales Market Share by Manufacturers Table 9. Global Cancer Drugs Average Sales Price (US$/ton) of Manufacturers (2021-2026) Table 10. Global Cancer Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Cancer Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Cancer Drugs Manufacturers, Product Type & Application Table 13. Global Cancer Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Cancer Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Targeted Therapy Table 17. Major Manufacturers of Hormonal Therapy (Biologic Therapy) Table 18. Major Manufacturers of Chemotherapy Table 19. Major Manufacturers of Immunotherapy Table 20. Major Manufacturers of Others Table 21. Global Cancer Drugs Sales by Type 2021 VS 2025 VS 2032 (k tons) Table 22. Global Cancer Drugs Sales by Type (2021-2026) & (k tons) Table 23. Global Cancer Drugs Sales by Type (2027-2032) & (k tons) Table 24. Global Cancer Drugs Sales Market Share by Type (2021-2026) Table 25. Global Cancer Drugs Sales Market Share by Type (2027-2032) Table 26. Global Cancer Drugs Revenue by Type 2021 VS 2025 VS 2032 (k tons) Table 27. Global Cancer Drugs Revenue by Type (2021-2026) & (k tons) Table 28. Global Cancer Drugs Revenue by Type (2027-2032) & (k tons) Table 29. Global Cancer Drugs Revenue Market Share by Type (2021-2026) Table 30. Global Cancer Drugs Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Blood Cancer Table 32. Major Manufacturers of Gastrointestinal Cancer Table 33. Major Manufacturers of Breast Cancer Table 34. Major Manufacturers of Prostate Cancer Table 35. Major Manufacturers of Respiratory/Lung Cancer Table 36. Major Manufacturers of Other Cancers Table 37. Global Cancer Drugs Sales by Application 2021 VS 2025 VS 2032 (k tons) Table 38. Global Cancer Drugs Sales by Application (2021-2026) & (k tons) Table 39. Global Cancer Drugs Sales by Application (2027-2032) & (k tons) Table 40. Global Cancer Drugs Sales Market Share by Application (2021-2026) Table 41. Global Cancer Drugs Sales Market Share by Application (2027-2032) Table 42. Global Cancer Drugs Revenue by Application 2021 VS 2025 VS 2032 (k tons) Table 43. Global Cancer Drugs Revenue by Application (2021-2026) & (k tons) Table 44. Global Cancer Drugs Revenue by Application (2027-2032) & (k tons) Table 45. Global Cancer Drugs Revenue Market Share by Application (2021-2026) Table 46. Global Cancer Drugs Revenue Market Share by Application (2027-2032) Table 47. Global Cancer Drugs Sales by Region: 2021 VS 2025 VS 2032 (k tons) Table 48. Global Cancer Drugs Sales by Region (2021-2026) & (k tons) Table 49. Global Cancer Drugs Sales Market Share by Region (2021-2026) Table 50. Global Cancer Drugs Sales Forecasted by Region (2027-2032) & (k tons) Table 51. Global Cancer Drugs Sales Forecasted Market Share by Region (2027-2032) Table 52. North America Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 53. North America Cancer Drugs Sales by Country (2021-2026) & (k tons) Table 54. North America Cancer Drugs Sales by Country (2027-2032) & (k tons) Table 55. Europe Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 56. Europe Cancer Drugs Sales by Country (2021-2026) & (k tons) Table 57. Europe Cancer Drugs Sales by Country (2027-2032) & (k tons) Table 58. Asia Pacific Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 59. Asia Pacific Cancer Drugs Sales by Country (2021-2026) & (k tons) Table 60. Asia Pacific Cancer Drugs Sales by Country (2027-2032) & (k tons) Table 61. South America, Middle East and Africa Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 62. South America, Middle East and Africa Cancer Drugs Sales by Country (2021-2026) & (k tons) Table 63. South America, Middle East and Africa Cancer Drugs Sales by Country (2027-2032) & (k tons) Table 64. Global Cancer Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 65. Global Cancer Drugs Revenue by Region (2021-2026) & (US$ Million) Table 66. Global Cancer Drugs Revenue by Region (2027-2032) & (US$ Million) Table 67. Global Cancer Drugs Revenue Market Share by Region (2021-2026) Table 68. Global Cancer Drugs Revenue Market Share by Region (2027-2032) Table 69. Takeda Company Information Table 70. Takeda Business Overview Table 71. Takeda Cancer Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Takeda Cancer Drugs Product Portfolio Table 73. Takeda Recent Development Table 74. Eisai Company Information Table 75. Eisai Business Overview Table 76. Eisai Cancer Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Eisai Cancer Drugs Product Portfolio Table 78. Eisai Recent Development Table 79. Teva Company Information Table 80. Teva Business Overview Table 81. Teva Cancer Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Teva Cancer Drugs Product Portfolio Table 83. Teva Recent Development Table 84. Sanofi Company Information Table 85. Sanofi Business Overview Table 86. Sanofi Cancer Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Sanofi Cancer Drugs Product Portfolio Table 88. Sanofi Recent Development Table 89. Johnson & Johnson Company Information Table 90. Johnson & Johnson Business Overview Table 91. Johnson & Johnson Cancer Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Johnson & Johnson Cancer Drugs Product Portfolio Table 93. Johnson & Johnson Recent Development Table 94. Novartis Company Information Table 95. Novartis Business Overview Table 96. Novartis Cancer Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Novartis Cancer Drugs Product Portfolio Table 98. Novartis Recent Development Table 99. Roche Company Information Table 100. Roche Business Overview Table 101. Roche Cancer Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Roche Cancer Drugs Product Portfolio Table 103. Roche Recent Development Table 104. Eli Lilly Company Information Table 105. Eli Lilly Business Overview Table 106. Eli Lilly Cancer Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Eli Lilly Cancer Drugs Product Portfolio Table 108. Eli Lilly Recent Development Table 109. Pfizer Company Information Table 110. Pfizer Business Overview Table 111. Pfizer Cancer Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Pfizer Cancer Drugs Product Portfolio Table 113. Pfizer Recent Development Table 114. Bayer Company Information Table 115. Bayer Business Overview Table 116. Bayer Cancer Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Bayer Cancer Drugs Product Portfolio Table 118. Bayer Recent Development Table 119. Amgen Company Information Table 120. Amgen Business Overview Table 121. Amgen Cancer Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Amgen Cancer Drugs Product Portfolio Table 123. Amgen Recent Development Table 124. AbbVie Company Information Table 125. AbbVie Business Overview Table 126. AbbVie Cancer Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. AbbVie Cancer Drugs Product Portfolio Table 128. AbbVie Recent Development Table 129. AstraZeneca Company Information Table 130. AstraZeneca Business Overview Table 131. AstraZeneca Cancer Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 132. AstraZeneca Cancer Drugs Product Portfolio Table 133. AstraZeneca Recent Development Table 134. Otsuka Company Information Table 135. Otsuka Business Overview Table 136. Otsuka Cancer Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 137. Otsuka Cancer Drugs Product Portfolio Table 138. Otsuka Recent Development Table 139. Merck KGaA Company Information Table 140. Merck KGaA Business Overview Table 141. Merck KGaA Cancer Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 142. Merck KGaA Cancer Drugs Product Portfolio Table 143. Merck KGaA Recent Development Table 144. Merck & Co. Company Information Table 145. Merck & Co. Business Overview Table 146. Merck & Co. Cancer Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 147. Merck & Co. Cancer Drugs Product Portfolio Table 148. Merck & Co. Recent Development Table 149. Ipsen Company Information Table 150. Ipsen Business Overview Table 151. Ipsen Cancer Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 152. Ipsen Cancer Drugs Product Portfolio Table 153. Ipsen Recent Development Table 154. Gilead Sciences Company Information Table 155. Gilead Sciences Business Overview Table 156. Gilead Sciences Cancer Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 157. Gilead Sciences Cancer Drugs Product Portfolio Table 158. Gilead Sciences Recent Development Table 159. Celgene Company Information Table 160. Celgene Business Overview Table 161. Celgene Cancer Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 162. Celgene Cancer Drugs Product Portfolio Table 163. Celgene Recent Development Table 164. Bristol-Myers Squibb Company Information Table 165. Bristol-Myers Squibb Business Overview Table 166. Bristol-Myers Squibb Cancer Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 167. Bristol-Myers Squibb Cancer Drugs Product Portfolio Table 168. Bristol-Myers Squibb Recent Development Table 169. Biogen Idec Company Information Table 170. Biogen Idec Business Overview Table 171. Biogen Idec Cancer Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 172. Biogen Idec Cancer Drugs Product Portfolio Table 173. Biogen Idec Recent Development Table 174. Astellas Company Information Table 175. Astellas Business Overview Table 176. Astellas Cancer Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 177. Astellas Cancer Drugs Product Portfolio Table 178. Astellas Recent Development Table 179. Key Raw Materials Table 180. Raw Materials Key Suppliers Table 181. Cancer Drugs Distributors List Table 182. Cancer Drugs Customers List Table 183. Research Programs/Design for This Report Table 184. Authors List of This Report Table 185. Secondary Sources Table 186. Primary Sources List of Figures Figure 1. Cancer Drugs Product Image Figure 2. Global Cancer Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Cancer Drugs Sales (2021-2032) & (k tons) Figure 5. Global Cancer Drugs Average Price (US$/ton) & (2021-2032) Figure 6. Global Top 5 and 10 Cancer Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Targeted Therapy Image Figure 9. Hormonal Therapy (Biologic Therapy) Image Figure 10. Chemotherapy Image Figure 11. Immunotherapy Image Figure 12. Others Image Figure 13. Global Cancer Drugs Sales by Type (2021 VS 2025 VS 2032) & (k tons) Figure 14. Global Cancer Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Cancer Drugs Sales Market Share by Type (2021-2032) Figure 16. Global Cancer Drugs Revenue by Type (2021 VS 2025 VS 2032) & (k tons) Figure 17. Global Cancer Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Cancer Drugs Revenue Market Share by Type (2021-2032) Figure 19. Blood Cancer Image Figure 20. Gastrointestinal Cancer Image Figure 21. Breast Cancer Image Figure 22. Prostate Cancer Image Figure 23. Respiratory/Lung Cancer Image Figure 24. Other Cancers Image Figure 25. Global Cancer Drugs Sales by Application (2021 VS 2025 VS 2032) & (k tons) Figure 26. Global Cancer Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 27. Global Cancer Drugs Sales Market Share by Application (2021-2032) Figure 28. Global Cancer Drugs Revenue by Application (2021 VS 2025 VS 2032) & (k tons) Figure 29. Global Cancer Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 30. Global Cancer Drugs Revenue Market Share by Application (2021-2032) Figure 31. North America Cancer Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 32. North America Cancer Drugs Sales Market Share by Country (2021-2032) Figure 33. U.S. Cancer Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 34. Canada Cancer Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 35. Mexico Cancer Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 36. Europe Cancer Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 37. Europe Cancer Drugs Sales Market Share by Country (2021-2032) Figure 38. Germany Cancer Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 39. France Cancer Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 40. U.K. Cancer Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 41. Italy Cancer Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 42. Netherlands Cancer Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 43. Asia Pacific Cancer Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 44. Asia Pacific Cancer Drugs Sales Market Share by Country (2021-2032) Figure 45. China Cancer Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 46. Japan Cancer Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 47. South Korea Cancer Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 48. Southeast Asia Cancer Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 49. India Cancer Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 50. Australia Cancer Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 51. South America, Middle East and Africa Cancer Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 52. South America, Middle East and Africa Cancer Drugs Sales Market Share by Country (2021-2032) Figure 53. Brazil Cancer Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 54. South Africa Cancer Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 55. Saudi Arabia Cancer Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 56. Turkey Cancer Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 57. Argentina Cancer Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 58. UAE Cancer Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 59. Egypt Cancer Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 60. Chile Cancer Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 61. Global Cancer Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Global Cancer Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 63. North America Cancer Drugs Revenue (2021-2032) & (US$ Million) Figure 64. North America Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Europe Cancer Drugs Revenue (2021-2032) & (US$ Million) Figure 66. Europe Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Asia-Pacific Cancer Drugs Revenue (2021-2032) & (US$ Million) Figure 68. Asia-Pacific Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. South America, Middle East and Africa Cancer Drugs Revenue (2021-2032) & (US$ Million) Figure 70. South America, Middle East and Africa Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 71. Cancer Drugs Value Chain Figure 72. Manufacturing Cost Structure Figure 73. Cancer Drugs Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • Targeted Therapy
  • Hormonal Therapy (Biologic Therapy)
  • Chemotherapy
  • Immunotherapy
  • Others
Applications
  • Blood Cancer
  • Gastrointestinal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Respiratory/Lung Cancer
  • Other Cancers
Companies covered
  • Takeda
  • Eisai
  • Teva
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Roche
  • Eli Lilly
  • Pfizer
  • Bayer
  • Amgen
  • AbbVie
  • AstraZeneca
  • Otsuka
  • Merck KGaA
  • Merck & Co.
  • Ipsen
  • Gilead Sciences
  • Celgene
  • Bristol-Myers Squibb
  • Biogen Idec
  • Astellas

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Cancer Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Cancer Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Cancer Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Cancer Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Cancer Drugs Market Dynamics
  1. 2.1 Cancer Drugs Industry Trends
  2. 2.2 Cancer Drugs Industry Drivers
  3. 2.3 Cancer Drugs Industry Opportunities and Challenges
  4. 2.4 Cancer Drugs Industry Restraints
3 Cancer Drugs Market by Manufacturers
  1. 3.1 Global Cancer Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Cancer Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Cancer Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Cancer Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Cancer Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Cancer Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Cancer Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Cancer Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Cancer Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Cancer Drugs Tier 1, Tier 2, and Tier 3
4 Cancer Drugs Market by Type
  1. 4.1 Cancer Drugs Type Introduction
  2. 4.1.1 Targeted Therapy
  3. 4.1.2 Hormonal Therapy (Biologic Therapy)
  4. 4.1.3 Chemotherapy
  5. 4.1.4 Immunotherapy
  6. 4.1.5 Others
  7. 4.2 Global Cancer Drugs Sales by Type
  8. 4.2.1 Global Cancer Drugs Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Cancer Drugs Sales by Type (2021-2032)
  10. 4.2.3 Global Cancer Drugs Sales Market Share by Type (2021-2032)
  11. 4.3 Global Cancer Drugs Revenue by Type
  12. 4.3.1 Global Cancer Drugs Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Cancer Drugs Revenue by Type (2021-2032)
  14. 4.3.3 Global Cancer Drugs Revenue Market Share by Type (2021-2032)
5 Cancer Drugs Market by Application
  1. 5.1 Cancer Drugs Application Introduction
  2. 5.1.1 Blood Cancer
  3. 5.1.2 Gastrointestinal Cancer
  4. 5.1.3 Breast Cancer
  5. 5.1.4 Prostate Cancer
  6. 5.1.5 Respiratory/Lung Cancer
  7. 5.1.6 Other Cancers
  8. 5.2 Global Cancer Drugs Sales by Application
  9. 5.2.1 Global Cancer Drugs Sales by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Cancer Drugs Sales by Application (2021-2032)
  11. 5.2.3 Global Cancer Drugs Sales Market Share by Application (2021-2032)
  12. 5.3 Global Cancer Drugs Revenue by Application
  13. 5.3.1 Global Cancer Drugs Revenue by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global Cancer Drugs Revenue by Application (2021-2032)
  15. 5.3.3 Global Cancer Drugs Revenue Market Share by Application (2021-2032)
6 Global Cancer Drugs Sales by Region
  1. 6.1 Global Cancer Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cancer Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Cancer Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Cancer Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Cancer Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Cancer Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Cancer Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Cancer Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Cancer Drugs Revenue by Region
  1. 7.1 Global Cancer Drugs Revenue by Region
  2. 7.1.1 Global Cancer Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Cancer Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Cancer Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Cancer Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Cancer Drugs Revenue (2021-2032)
  8. 7.2.2 North America Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Cancer Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Cancer Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Cancer Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Cancer Drugs Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Eisai
  8. 8.2.1 Eisai Company Information
  9. 8.2.2 Eisai Business Overview
  10. 8.2.3 Eisai Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eisai Cancer Drugs Product Portfolio
  12. 8.2.5 Eisai Recent Developments
  13. 8.3 Teva
  14. 8.3.1 Teva Company Information
  15. 8.3.2 Teva Business Overview
  16. 8.3.3 Teva Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Teva Cancer Drugs Product Portfolio
  18. 8.3.5 Teva Recent Developments
  19. 8.4 Sanofi
  20. 8.4.1 Sanofi Company Information
  21. 8.4.2 Sanofi Business Overview
  22. 8.4.3 Sanofi Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sanofi Cancer Drugs Product Portfolio
  24. 8.4.5 Sanofi Recent Developments
  25. 8.5 Johnson & Johnson
  26. 8.5.1 Johnson & Johnson Company Information
  27. 8.5.2 Johnson & Johnson Business Overview
  28. 8.5.3 Johnson & Johnson Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Johnson & Johnson Cancer Drugs Product Portfolio
  30. 8.5.5 Johnson & Johnson Recent Developments
  31. 8.6 Novartis
  32. 8.6.1 Novartis Company Information
  33. 8.6.2 Novartis Business Overview
  34. 8.6.3 Novartis Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novartis Cancer Drugs Product Portfolio
  36. 8.6.5 Novartis Recent Developments
  37. 8.7 Roche
  38. 8.7.1 Roche Company Information
  39. 8.7.2 Roche Business Overview
  40. 8.7.3 Roche Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Roche Cancer Drugs Product Portfolio
  42. 8.7.5 Roche Recent Developments
  43. 8.8 Eli Lilly
  44. 8.8.1 Eli Lilly Company Information
  45. 8.8.2 Eli Lilly Business Overview
  46. 8.8.3 Eli Lilly Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Eli Lilly Cancer Drugs Product Portfolio
  48. 8.8.5 Eli Lilly Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer Cancer Drugs Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
  55. 8.10 Bayer
  56. 8.10.1 Bayer Company Information
  57. 8.10.2 Bayer Business Overview
  58. 8.10.3 Bayer Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bayer Cancer Drugs Product Portfolio
  60. 8.10.5 Bayer Recent Developments
  61. 8.11 Amgen
  62. 8.11.1 Amgen Company Information
  63. 8.11.2 Amgen Business Overview
  64. 8.11.3 Amgen Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Amgen Cancer Drugs Product Portfolio
  66. 8.11.5 Amgen Recent Developments
  67. 8.12 AbbVie
  68. 8.12.1 AbbVie Company Information
  69. 8.12.2 AbbVie Business Overview
  70. 8.12.3 AbbVie Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 AbbVie Cancer Drugs Product Portfolio
  72. 8.12.5 AbbVie Recent Developments
  73. 8.13 AstraZeneca
  74. 8.13.1 AstraZeneca Company Information
  75. 8.13.2 AstraZeneca Business Overview
  76. 8.13.3 AstraZeneca Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 AstraZeneca Cancer Drugs Product Portfolio
  78. 8.13.5 AstraZeneca Recent Developments
  79. 8.14 Otsuka
  80. 8.14.1 Otsuka Company Information
  81. 8.14.2 Otsuka Business Overview
  82. 8.14.3 Otsuka Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Otsuka Cancer Drugs Product Portfolio
  84. 8.14.5 Otsuka Recent Developments
  85. 8.15 Merck KGaA
  86. 8.15.1 Merck KGaA Company Information
  87. 8.15.2 Merck KGaA Business Overview
  88. 8.15.3 Merck KGaA Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Merck KGaA Cancer Drugs Product Portfolio
  90. 8.15.5 Merck KGaA Recent Developments
  91. 8.16 Merck & Co.
  92. 8.16.1 Merck & Co. Company Information
  93. 8.16.2 Merck & Co. Business Overview
  94. 8.16.3 Merck & Co. Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Merck & Co. Cancer Drugs Product Portfolio
  96. 8.16.5 Merck & Co. Recent Developments
  97. 8.17 Ipsen
  98. 8.17.1 Ipsen Company Information
  99. 8.17.2 Ipsen Business Overview
  100. 8.17.3 Ipsen Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Ipsen Cancer Drugs Product Portfolio
  102. 8.17.5 Ipsen Recent Developments
  103. 8.18 Gilead Sciences
  104. 8.18.1 Gilead Sciences Company Information
  105. 8.18.2 Gilead Sciences Business Overview
  106. 8.18.3 Gilead Sciences Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Gilead Sciences Cancer Drugs Product Portfolio
  108. 8.18.5 Gilead Sciences Recent Developments
  109. 8.19 Celgene
  110. 8.19.1 Celgene Company Information
  111. 8.19.2 Celgene Business Overview
  112. 8.19.3 Celgene Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Celgene Cancer Drugs Product Portfolio
  114. 8.19.5 Celgene Recent Developments
  115. 8.20 Bristol-Myers Squibb
  116. 8.20.1 Bristol-Myers Squibb Company Information
  117. 8.20.2 Bristol-Myers Squibb Business Overview
  118. 8.20.3 Bristol-Myers Squibb Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Bristol-Myers Squibb Cancer Drugs Product Portfolio
  120. 8.20.5 Bristol-Myers Squibb Recent Developments
  121. 8.21 Biogen Idec
  122. 8.21.1 Biogen Idec Company Information
  123. 8.21.2 Biogen Idec Business Overview
  124. 8.21.3 Biogen Idec Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Biogen Idec Cancer Drugs Product Portfolio
  126. 8.21.5 Biogen Idec Recent Developments
  127. 8.22 Astellas
  128. 8.22.1 Astellas Company Information
  129. 8.22.2 Astellas Business Overview
  130. 8.22.3 Astellas Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Astellas Cancer Drugs Product Portfolio
  132. 8.22.5 Astellas Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Cancer Drugs Value Chain Analysis
  2. 9.1.1 Cancer Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Cancer Drugs Production Mode & Process
  6. 9.2 Cancer Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Cancer Drugs Distributors
  9. 9.2.3 Cancer Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst